Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study
Alan K. Percy, Jeffrey L. Neul, Tim A. Benke, et al.
Med (2024) Vol. 5, Iss. 9, pp. 1178-1189.e3
Open Access | Times Cited: 14

Showing 14 citing articles:

Development of trofinetide for the treatment of Rett syndrome: from bench to bedside
Melissa Kennedy, Larry Glass, Daniel G. Glaze, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 8
Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Clinical Trials
Amy Barrett, Oyebimpe Olayinka-Amao, Susan Martin, et al.
Clinical Therapeutics (2025)
Open Access | Times Cited: 1
Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study
Alan K. Percy, Jeffrey L. Neul, Tim A. Benke, et al.
Med (2024) Vol. 5, Iss. 10, pp. 1275-1281.e2
Open Access | Times Cited: 7
Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives
Rebecca Moore, Joshua Poulsen, Lindsay Reardon, et al.
Advances in Therapy (2024) Vol. 41, Iss. 4, pp. 1305-1317
Open Access | Times Cited: 4
Assessing the effects of trofinetide on QTc interval, safety and tolerability, and pharmacokinetics in healthy adults
Mona Darwish, James M. Youakim, Jay W. Mason, et al.
Future Rare Diseases (2025) Vol. 5, Iss. 1
Open Access
Rett Syndrome Behaviour Questionnaire: Variability of Scores and Related Factors
Walter E. Kaufmann, Lindsay M. Oberman, Jenny Downs, et al.
Journal of Child and Adolescent Psychopharmacology (2025)
Closed Access
Results from the phase 2/3 DAFFODIL study of trofinetide in girls aged 2–4 years with Rett syndrome
Alan K. Percy, Robin Ryther, Eric D. Marsh, et al.
Med (2025), pp. 100608-100608
Open Access
A Blueprint for Translational Precision Medicine in Autism Spectrum Disorder and Related Neurogenetic Syndromes
Robyn P. Thom, Tracy L. Warren, Suha Khan, et al.
Journal of Child and Adolescent Psychopharmacology (2025)
Closed Access
Is trofinetide a future treatment for Rett syndrome? A comprehensive systematic review and meta-analysis of randomized controlled trials
Hazem Mohammed, Zeyad Bady, Mohamed E. Haseeb, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Using Precision Medicine to Disentangle Genotype–Phenotype Relationships in Twins with Rett Syndrome: A Case Report
Jatinder Singh, Georgina Wilkins, Ella Goodman-Vincent, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 8, pp. 8424-8440
Open Access | Times Cited: 1
Profile of Trofinetide in the Treatment of Rett Syndrome: Design, Development and Potential Place in Therapy
Laura Camillo, Marco Pozzi, Pia Bernardo, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 5023-5040
Open Access | Times Cited: 1
Autism interventions tailored for Black Americans; gene therapy for Rett syndrome; KATNAL2 gene
Jill Adams
The Transmitter (2024)
Closed Access
Improvement in symptoms of Rett syndrome with trofinetide beyond clinical trial efficacy assessments: case reports
Robin C. Ryther, Christine Palladino, Sanjeev V. Kothare
Future Rare Diseases (2024) Vol. 4, Iss. 1
Open Access
Trofinetide treatment for Rett syndrome: Lessons to learn
Daniela Tropea
Med (2024) Vol. 5, Iss. 10, pp. 1194-1196
Closed Access
Page 1

Scroll to top